Ovagen

Ovagen is a synthetic tripeptide with the sequence Glu-Asp-Leu (glutamyl-aspartyl-leucine; abbreviation EDL), commercially designated peptide complex AC-3. Its molecular formula is C15H25N3O8 (molecular weight 375.37 g/mol). The compound belongs to the class of short-peptide bioregulators developed at the St. Petersburg Institute of Bioregulation and Gerontology by Vladimir Khavinson and colleagues.

The proposed primary mechanism involves nuclear penetration and direct interaction with genomic DNA. Molecular docking studies by Khavinson et al. (2016; PMID 27909961), modelling interactions of 19 short peptides with DNA, found that the EDL tripeptide preferentially associates with CTCC nucleotide sequences within gene promoter regions. This binding is hypothesized to reduce local chromatin condensation, rendering previously silenced promoters accessible for transcription in a tissue-specific manner.

In aged cell cultures, the peptide is proposed to downregulate pro-apoptotic and senescence-associated proteins including p53, p16, and p21, while upregulating SIRT-6, a chromatin-regulatory deacetylase linked to genomic stability. Activation of Nrf2-mediated antioxidant pathways and suppression of NF-kB inflammatory signaling have also been proposed, but these mechanisms rest on computational and cell-culture data rather than confirmed human pharmacology. The tripeptide's small size facilitates uptake via intestinal peptide transporters PepT1 and PepT2, enabling systemic bioavailability after oral administration.

The clinical evidence base for Ovagen is narrow. All identifiable primary research originates from a single institution, and no independently replicated randomized controlled trials have been published in major international peer-reviewed journals.

In vitro: Khavinson et al. (2014; PMID 25946838) studied EDL alongside the AED tripeptide in aged renal tubular cell cultures. The study reported increased cell proliferation, reduced expression of senescence markers p16, p21, and p53, and elevated SIRT-6 levels. This is the most directly traceable preclinical study for the EDL sequence, though it was conducted in kidney cells, not hepatocytes.

Computational: Khavinson et al. (2016; PMID 27909961) used molecular docking to map preferred DNA binding sites for 19 short peptides. EDL was shown to interact favorably with CTCC sequences. This study supports the mechanistic hypothesis of gene-promoter interaction but is not a functional cellular study.

Related liver bioregulators: Kuznik et al. (2020; PMID 32362099) studied KEDA (Livagen, a distinct liver-targeted tetrapeptide) and a polypeptide liver complex in animal hepatitis models. Results showed normalization of liver enzymes and antioxidant status. These findings are sometimes cited alongside Ovagen in commercial literature but involve separate compounds.

Clinical claims specific to Ovagen: Manufacturer and distributor materials reference a Russian-language clinical study of patients with chronic hepatitis and chemotherapy-associated liver dysfunction, reportedly showing approximately 26% reduction in ALT levels, decreased bilirubin, and symptomatic improvements including reduced fatigue and abdominal pain. The original publication, sample size, methodology, and controls could not be independently verified through indexed English-language sources. Broader claims of an 18-fold increase in Ki-67 proliferation markers in aged liver tissue similarly lack a traceable peer-reviewed citation. The evidence for Ovagen's hepatic effects must therefore be characterized as preliminary and unvalidated by Western scientific standards.

Typical dosage: 10 mg (daily for cycles).

Ovagen is available commercially in two primary formulations.

Oral capsules: Each capsule contains 10 mg of peptide complex AC-3. Standard manufacturer guidance for adults (aged 14 and older) is 1 to 2 capsules taken once or twice daily with meals, for a course of 10 to 30 days. Repeat courses are typically recommended 2 to 3 times per year, with a minimum interval of 3 to 4 months between cycles. A full therapeutic month requires 1 to 3 packages depending on frequency.

Sublingual liquid: Available as a 10 ml solution containing approximately 0.1 mg peptide complex AC-3 per ml. The recommended daily dose is 2 to 5 ml, divided into 3 to 4 applications held briefly under the tongue before swallowing. Once opened, the solution should be refrigerated and consumed within 10 to 14 days. A single 10 ml bottle corresponds to approximately one cycle.

Community and vendor literature for injectable research-grade preparations suggests 20 units subcutaneously before bed for a 20-day initial course, with 10-day maintenance cycles every 3 to 6 months. This route has no clinical trial support and should be regarded as entirely anecdotal.

This information is provided for educational and encyclopedic reference purposes only and does not constitute medical advice. No dosing regimen for Ovagen has been validated in a properly controlled clinical trial, and appropriate use should be discussed with a qualified healthcare professional.

No compound-specific stability data has been identified for this peptide. The general lyophilized-peptide handling framework applies — see Storage & handling for temperature, reconstitution diluent, and beyond-use dating principles.

All combination strategies described here are anecdotal or derived from community practice and commercial vendor recommendations. No controlled studies of Ovagen in combination with other agents have been published.

Ovagen is frequently paired with other Khavinson-series peptide bioregulators in multi-compound protocols. A commonly cited combination is Ovagen with Livagen (KEDA tetrapeptide, also liver-targeted) and Vesugen (vascular bioregulator), on the rationale that the three peptides address distinct but overlapping aspects of hepatic function, microvascular integrity, and immune-antioxidant status. Some vendor literature describes a so-called Stack 3 protocol comprising Ovagen (200 mg total per cycle), Cartalax (cartilage bioregulator, 300 mg), and Livagen (100 mg) taken over 20 to 30 day cycles repeated every 3 to 6 months; this is a commercial construct with no clinical trial support.

Conventional hepatoprotective supplements including milk thistle (silymarin), N-acetylcysteine, tauroursodeoxycholic acid (TUDCA), and B-complex vitamins are sometimes co-administered alongside Ovagen. The rationale is that these agents address distinct injury pathways (antioxidant defense, mitochondrial support, bile acid homeostasis) not directly targeted by the peptide. This is pharmacologically plausible reasoning, not evidence from combination studies.

Ovagen is not currently FDA-approved for any indication. It is generally classified as a research compound. Regulatory status varies by country.

PeptideSciences101 does not endorse vendors. For transparency metrics and third-party testing notes, see the vendor directory.

Reported side effects: Generally safe

Manufacturer and distributor labeling consistently states that Ovagen produces no identified side effects, complications, or drug dependence when used as directed. This claim, repeated across multiple vendor sources, has not been verified by independent safety pharmacology studies, formal pharmacovigilance systems, or regulatory review in any major jurisdiction.

Mild adverse effects reported in user community and commercial sources include transient nausea, temporary bloating, and minor digestive discomfort, typically self-resolving within 1 to 3 days of initiation. These are attributed to GI mucosal adaptation.

Stated contraindications across available product labeling include: known allergy to gelatin or lactose (capsule excipients); pregnancy and breastfeeding (no safety data exist); acute liver failure; acute-phase viral hepatitis; Wilson's disease; and use in children under 14 to 18 years (formulation-dependent). One vendor cautions users to discontinue if dizziness, tremors, insomnia, headache, palpitations, or tingling occur, though these adverse signals have not been reported in any published study.

Potential drug interactions have not been formally studied. Theoretical concerns exist around cytochrome P450 substrates, immunosuppressants, and anticoagulants, given the proposed modulation of Nrf2 and NF-kB pathways that influence drug-metabolizing enzymes. The compound has not received regulatory approval from the FDA, EMA, or other major agencies. The absence of formal pharmacovigilance and the reliance on manufacturer self-reporting for all safety claims should be weighed carefully.